Navigation Links
VaxGen Reports Financial Update
Date:3/6/2008

December 31,

2007 2006

Assets

Current assets:

Cash and cash equivalents:

Cash and commercial paper $ 64,726 $18,697

Reverse repurchase agreements - 54,378

Total cash and cash equivalents 64,726 73,075

Investment securities 6,889 24,668

Accounts receivable 199 516

Unbilled accounts receivable - 7,164

Due from related party - 284

Prepaid expenses and other current assets 1,167 2,544

Total current assets 72,981 108,251

Property and equipment, net 10,806 28,417

Restricted cash 1,556 2,895

Other assets 4,622 2,497

Total assets $89,965 $142,060

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $2,151 $4,660

Accrued and other current liabilities 2,326 5,553

Derivative liability 3,500 8,220

Due to related party - 57

Total current liabilities 7,977 18,490

Convertible senior subordinated notes 30,679 30,321

Deferred rent and other liabilities 4,270 4,188

Total liabilities 42,926 52,999

Stockholders' equity:

Preferred sto
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
2. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
3. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
4. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
5. VaxGen Addresses MPM Claims in Letter to Stockholders
6. VaxGen Files Last Outstanding Periodic Report With SEC
7. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
8. VaxGen Files First Quarter 2007 Financials
9. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Audacity, ... activation agency and member of the Huntsworth Health Group, ... to its executive team. In her role, Gonzales will ... , “We are incredibly honored to welcome a talent ... Chief and CEO, Gaëtan Fraikin. “She is a proven ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... has launched interactive, personalized services for Milwaukee drivers ... company announced Thursday. Traffic.com will provide area commuters ... of roadway traffic conditions including congestion levels, incidents, ... a news release. , ,Data for the site ...
... expanded its business continuance practice with Data Storage ... new service provides customers with off-site, secure data ... data. The disk-based system delivers high-speed transfer and ... systems, the company said. , , Norlight ...
... Tascon Group has launched the Tascon Business Analyst online, offering ... , ,The Business Analyst is being offered as a licensed ... ,The program is based on a business valuation method developed ... system known as the optimization method. , ,"It is based ...
Cached Biology Technology:
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... Like a homeowner prepping for a hurricane, the bacterium ... survival in hard times. In a new study, scientists at ... mechanism that allows B. subtilis to begin preparing ... whether to "hunker down" and withdraw into a hardened spore. ...
... /PRNewswire-iReach/ -- 3dMD, the 3D surface imaging system and ... for more than a decade, announces the availability of ... System to support serious research into quantifying and measuring ... systems have focused on generating virtual avatar effects for ...
... More than a century ago, a brilliant young ... Prize for her ground-breaking discoveries in radioactivity. ... of Chemistry, is carrying on Curie,s spirit of trail-blazing ... in Curie,s name. Last summer, Martn Rodrguez was ...
Cached Biology News:Deciphering bacterial doomsday decisions 2Deciphering bacterial doomsday decisions 33dMD Transitions Anatomical Research from 3D-Static to 4D-Movement Surface Imaging 23dMD Transitions Anatomical Research from 3D-Static to 4D-Movement Surface Imaging 3Following in Marie Curie's footsteps 2
... consists of two components used for alkaline ... ES cell-specific antibodies required to perform 100 ... become the subject of extensive investigation recently, ... because they raise several fundamental issues concerning ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... lication: For use as a ... and precipitation. Physical form: Solution ... pH 7.4, 1 mM EDTA ... precipitated Concentration: ...
... DTT White solid.. PACKAGED UNDER INERT ... so reaction is "driven" to completion. A protective ... surfactant found in many other preparations. Blocks the ... ≥97% by titration. Contaminants: Heavy metals: ...
Biology Products: